Background: Epilepsy is a neurological condition with an increased probability of seizure
occurrence through time. Although many anti-epileptic drugs (AEDs) exist, they fail to treat …

Epilepsy is a common neurological disorder. Despite a broad range of commonly used
antiepileptic drugs, approximately 30% of patients with epilepsy have drug resistance or …

Eslicarbazepine acetate (ESL) is a novel antiepileptic drug indicated for the treatment of
partial-onset seizures. Structurally, it belongs to the dibenzazepine family and is closely …

INTRODUCTION. Eslicarbazepine acetate (ESL) is a new antiepileptic drug (AED) licensed
in Spain in February 2011 as an adjunctive therapy in adults with partial seizures with or …

Eslicarbazepine acetate (ESL) is a once daily new third generation antiepileptic drug that
shares the basic chemical structure of carbamazepine and oxcarbazepine–a dibenzazepine …

Eslicarbazepine acetate is a new anti-epileptic drug belonging to the dibenzazepine
carboxamide family that is currently approved as adjunctive therapy and monotherapy for …

Eslicarbazepine acetate (ESL) is a once-daily antiepileptic drug that is approved as
adjunctive therapy in adults with focal-onset seizures. Following oral administration, ESL is …

Introduction: Eslicarbazepine acetate (ESL) is a third-generation antiepileptic drug (AED)
approved for adjunctive treatment in adults, children, and adolescents with focal-onset …

Background Eslicarbazepine acetate (ESL) is a new antiepileptic drug (AED) licensed as
adjunctive therapy in adults with partial-onset or focal seizures. Objective To evaluate in a …

Introduction: Up to 30% of the patients diagnosed with epilepsy will continue suffering from
seizures despite treatment with antiepileptic drugs, either in monotherapy or polytherapy …